| Literature DB >> 28868112 |
Jae Seung Soh1, Hyun Lim1, Ho Suk Kang1, Jong Hyeok Kim1, Kab Choong Kim1.
Abstract
AIM: To investigate the clinicopathological variables in early gastric cancer (EGC) patients in relation to differentiation discrepancy.Entities:
Keywords: Clinicopathological factor; Differentiation; Early gastric cancer; Endoscopic treatment; Histological discrepancy; Surgical treatment
Year: 2017 PMID: 28868112 PMCID: PMC5561043 DOI: 10.4251/wjgo.v9.i8.319
Source DB: PubMed Journal: World J Gastrointest Oncol
Tumor differentiation between preoperative biopsies and postoperative specimens
| Differentiated | WD | 56 | 12 | 0 |
| MD | 24 | 45 | 2 | |
| Undifferentiated | PD | 4 | 19 | 103 |
PD: Poorly differentiated; MD: Moderately differentiated; WD: Well differentiated.
Clinical characteristics of 240 patients and tumor characteristics in 265 specimens n (%)
| Age ( | |||
| Median, yr (range) | 58 (31-83) | 61 (35-90) | 0.073 |
| Sex ( | |||
| Male | 17 (70.8) | 147 (68.1) | 0.781 |
| Female | 7 (29.2) | 69 (31.9) | |
| Underlying disease | |||
| Yes | 12 (50.0) | 100 (46.3) | 0.730 |
| No | 12 (50.0) | 116 (53.7) | |
| Location ( | |||
| Upper | 4 (16.0) | 17 (7.1) | 0.776 |
| Middle | 10 (40.0) | 130 (54.2) | |
| Lower | 11 (44.0) | 93 (38.8) | |
| Gross pattern ( | |||
| Elevated | 1 (4.0) | 22 (9.2) | 0.668 |
| Flat | 5 (20.0) | 42 (17.5) | |
| Depressed | 10 (40.0) | 93 (38.8) | |
| Mixed elevated | 2 (8.0) | 24 (10.0) | |
| Mixed flat | 4 (16.0) | 31 (12.9) | |
| Mixed depressed | 3 (12.0) | 28 (11.7) | |
| Ulcer ( | |||
| Positive | 12 (48.0) | 100 (41.7) | 0.542 |
| Negative | 13 (52.0) | 140 (58.3) | |
| Erythema ( | |||
| Positive | 5 (20.0) | 52 (21.7) | 0.847 |
| Negative | 20 (80.0) | 188 (78.3) | |
| Fold change ( | |||
| Positive | 20 (80.0) | 109 (45.4) | 0.001 |
| Negative | 5 (20.0) | 131 (54.9) | |
| Easy friability ( | |||
| Positive | 9 (36.0) | 84 (35.0) | 0.921 |
| Negative | 16 (64.0) | 156 (65.0) | |
| Exudate ( | |||
| Positive | 5 (20.0) | 36 (15.0) | 0.511 |
| Negative | 20 (80.0) | 204 (85.0) | |
| Number of biopsies ( | |||
| Median (range) | 3 (2-6) | 3 (1-10) | 0.332 |
| Follow-up period (mo) ( | |||
| Median (range) | 41 (2-72) | 36 (2-76) | 0.629 |
| Recurrences during follow-up ( | 1 (4.2) | 2 (0.9) | 0.272 |
| Death during follow-up ( | 0 (0.0) | 4 (1.9) | 1.000 |
Underlying diseases include hypertension, diabetes, and cardiovascular, cerebrovascular, and pulmonary diseases.
Histopathological characteristics of surgical specimens n (%)
| Tumor size in the specimen ( | |||
| Median, cm (range) | 3.0 (0.8-5.5) | 2.2 (0.4-8.5) | 0.252 |
| Tumor staging ( | |||
| Ia | 7 (28.0) | 121 (50.4) | 0.033 |
| Ib | 18 (72.0) | 119 (49.6) | |
| Nodal staging ( | |||
| Positive | 6 (24.0) | 19 (7.9) | 0.009 |
| Negative | 19 (76.0) | 221 (92.1) | |
| Lymphatic invasion ( | |||
| Positive | 7 (28.0) | 41 (17.1) | 0.177 |
| Negative | 18 (72.0) | 199 (82.9) | |
| Vascular invasion ( | |||
| Positive | 2 (8.0) | 17 (7.1) | 0.697 |
| Negative | 23 (92.0) | 223 (92.9) | |
| Ki-67 ( | |||
| High | 20 (95.2) | 186 (83.8) | 0.215 |
| Low | 1 (4.8) | 36 (16.2) | |
| p53 ( | |||
| Positive | 15 (71.4) | 138 (62.2) | 0.401 |
| Negative | 6 (28.6) | 84 (37.8) | |
| HER2 ( | |||
| Positive (2+ and 3+) | 7 (33.3) | 41 (18.5) | 0.102 |
| Negative (0 and 1+) | 14 (66.7) | 181 (81.5) | |
| EGFR ( | |||
| Positive | 17 (81.0) | 123 (55.4) | 0.035 |
| Negative | 4 (19.0) | 99 (44.6) |
HER2: Human epidermal growth factor 2; EGFR: Epidermal growth factor receptor.
Comparison of histopathological characteristics between 23 specimens having discrepancy and 103 specimens having non-discrepancy along with undifferentiated postoperative histology n (%)
| Tumor size in the specimen ( | |||
| Median, cm (range) | 3.0 (0.8-5.5) | 2.5 (0.5-8.0) | 0.343 |
| Number of biopsies ( | |||
| Median, No. (range) | 3 (2-6) | 3 (1-8) | 0.374 |
| Location ( | |||
| Upper | 3 (13.0) | 10 (9.7) | 0.481 |
| Middle | 10 (43.5) | 62 (60.2) | |
| Lower | 10 (43.5) | 31 (30.1) | |
| Gross pattern ( | |||
| Elevated | 1 (4.3) | 1 (1.0) | 0.615 |
| Flat | 4 (17.4) | 20 (19.4) | |
| Depressed | 9 (39.1) | 51 (49.5) | |
| Mixed elevated | 2 (8.7) | 6 (5.8) | |
| Mixed flat | 4 (17.4) | 16 (15.5) | |
| Mixed depressed | 3 (13.0) | 9 (8.7) | |
| Tumor staging ( | |||
| Ia | 6 (26.1) | 52 (50.5) | 0.034 |
| Ib | 17 (73.9) | 51 (49.5) | |
| Nodal staging ( | |||
| Positive | 6 (26.1) | 9 (8.7) | 0.020 |
| Negative | 17 (73.9) | 94 (91.3) | |
| Lymphatic invasion ( | |||
| Positive | 7 (30.4) | 12 (11.7) | 0.023 |
| Negative | 16 (69.6) | 91 (88.3) | |
| Vascular invasion ( | |||
| Positive | 2 (8.7) | 2 (1.9) | 0.152 |
| Negative | 21 (91.3) | 101 (98.1) | |
| Ki-67 ( | |||
| High | 48 (94.7) | 77 (76.2) | 0.119 |
| Low | 1 (5.3) | 24 (23.8) | |
| p53 ( | |||
| Positive | 13 (68.4) | 59 (58.4) | 0.414 |
| Negative | 6 (31.6) | 42 (41.6) | |
| HER2 ( | |||
| Positive (2+ and 3+) | 7 (36.8) | 16 (15.8) | 0.033 |
| Negative (0 and 1+) | 12 (63.2) | 85 (84.2) | |
| EGFR ( | |||
| Positive | 16 (84.2) | 52 (51.5) | 0.011 |
| Negative | 3 (15.8) | 49 (48.5) |
HER2: Human epidermal growth factor 2; EGFR: Epidermal growth factor receptor.